Darzalex Q3 2026 net sales reach $4.24 billion, reports Genmab
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Crude Inventory Fell 3.06 Million Barrels Last Week - EIA
- US orders diplomats to depart Saudi Arabia amid Houthi strikes
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2026
October 13, 2026 6:22 AM EDTCompany Announcement
Net sales of DARZALEX® in the third quarter of 2026 totaled USD 4,239 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.)COPENHAGEN, Denmark; October 13, 2026 Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX... More



